NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Amplifier Therapeutics, a Cambrian Bio pipeline company, today announced the dosing of the first patient in the company's Phase 1B clinical trial investigating ATX-304, a peripherally restricted pan-AMPK activator being developed for the treatment of cardiometabolic diseases.
Lumen Bioscience gets $16M to advance C. diff therapy: The Department of Defense awarded $16.2 million to the Seattle-based company, which is developing an oral drug to treat and prevent infections with C. difficile. It plans to start enrolling 375 patients in a late-stage trial for LMN-201 by the end of the year.